Dolly the clone turned out to be one of a kind
Print Edition
WHEN Dolly the cloned sheep was born 20 years ago on July 5, many hailed mankind’s new-found mastery over DNA as a harbinger of medical miracles such as lab-grown transplant organs.
Others trembled at the portent of a “Brave New World” of identical humans farmed for spare parts or as cannon fodder.
As it turns out, neither came to pass.
Human cloning — complicated, risky and ethically contentious — has largely been replaced as the holy grail of regenerative medicine by other technologies, say experts.
“It has not lived (up) to the hype,” said Rosario Isasi of the University of Miami’s Institute for Bioethics and Health Policy.
“It was like a eureka moment: that we will finally be able to understand more (about) the mechanisms of disease, be able to maybe use it as a treatment for infertility,” she said. “But that has not happened.”
Arguably the world’s most famous sheep, Dolly was the first mammal cloned using a technique called somatic-cell nuclear transfer (SCNT).
It involves removing the DNA-containing nucleus of a cell other than an egg or sperm — a skin cell, for example — and implanting it into an unfertilized egg from which the nucleus has been removed.
In Dolly’s case, the gene-encoding cell was taken from a mammary gland, which saw the ewe named for buxom country singer Dolly Parton.
Once transferred, the egg reprograms the mature DNA back to an embryonic state with the aid of an electric jolt, and starts dividing to form a single-parent embryo.
No human is known to ever have been created in this way.
Cloning as a human reproductive technique is a global no-no.
Apart from ethical and human rights objections raised to the creation of carbon-copy people, safety is a key concern. In animals, only a handful of cloned embryos survive to birth, and many have health problems later.
Experts say moral opposition to cloning as a means of reproduction, has clouded opinion on the technique’s potential usefulness in regenerative medicine.
Mainly, people fear that scientists will not be able to resist the temptation of playing God.
“With the ethical safeguards in place, there’s... no way to go into reproductive applications,” insisted Isasi.
Yet, many people “fear that slippery slope...that one thing leads to another, leads to another, until there is a bad result.
“That’s the main concern. That is probably what has held back the use of the technology.”
Investment in therapeutic cloning research has dwindled, and few countries — among them Belgium, China, Israel, Japan, South Korea, Britain, Singapore — allow the creation of embryos for experimentation.
In therapeutic cloning, scientists harvest stem cells from a very early-stage embryo — called a blastocyst — a hollow ball of about 100-200 cells.
Coaxing these “blank”, juvenile cells into specialized liver or blood cells, for example, holds the promise of curing disease or repairing damaged organs.
If grown from the patient’s own DNA, the risk of transplant rejection is dramatically lowered.
But producing stem cells this way involves destroying embryos, another moral quagmire. And while a handful of scientists have succeeded in creating stem cells through SCNT, none have been grown into a functional human organ.
Cloning may not have found a direct application in medicine, but it has yielded many spinoff technologies, experts say.
“The whole field has moved to IPS cell research,” said Julian Savulescu, who heads Oxford University’s Uehiro Centre for Practical Ethics.
Induced pluripotent stem cells are created by stimulating mature, already specialized, cells back into a juvenile state — basically cloning without the need for an embryo.
Another spinoff is mitochondrial gene transfer, a new way of planting parental DNA into a healthy egg to create an embryo free of harmful mutations carried by the mother.
But human cloning, said Aaron Levine, a bioethicist at Georgia Tech, will disappear.
“I think there’s just not ultimately enough demand, not enough that you can do through cloning that you can’t do through other things.”
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
